Cardiac mesenchymal progenitors from postmortem cardiac tissues retained cellular characterization.
1Department of Regenerative Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Transplantation Proceedings
|May 13, 2014
Summary
Allogeneic cardiac mesenchymal progenitors (CMPs) from postmortem hearts show promise for regenerative medicine. These cells overcome limitations in donor cell quality and quantity for transplantation therapies.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Cell Biology
Background:
- Current cell transplantation relies on autologous or allogeneic tissues.
- Autologous cells face limitations in patient-dependent quality and quantity.
- Allogeneic cells may present immune compatibility challenges.
Purpose of the Study:
- Investigate the potential of allogeneic cardiac mesenchymal progenitors (CMPs) from postmortem hearts.
- Assess if postmortem CMPs are immunologically privileged, similar to bone marrow progenitors.
- Determine viability and characteristics of CMPs isolated from postmortem cardiac tissue.
Main Methods:
- Isolated CMPs from C57/B6 murine cardiac tissue 24 hours postmortem.
- Propagated cells for 2-3 weeks with high-dose basic fibroblast growth factor.
- Performed cellular characteristic analyses including proliferation, differentiation, flow cytometry, and microarray.
Main Results:
- Postmortem CMPs exhibited a longer lag phase but similar characteristics to live-tissue derived CMPs.
- Flow cytometry and microarray analyses confirmed comparable cellular properties.
- Global gene expression profiles were similar between postmortem and living tissue-derived CMPs.
Conclusions:
- Allogeneic postmortem CMPs are viable candidates for cell transplantation.
- These cells address donor cell quality and quantity limitations.
- Postmortem CMPs offer a potential solution for regenerative medicine applications.
